Differential prioritization of therapies to subtypes of triple negative breast cancer using a systems medicine method
Henri Wathieu(Georgetown University), Sivanesan Dakshanamurthy(Georgetown University), Deanna Tiek(Northwestern University), Rebecca B. Riggins(Georgetown University), Stephen W. Byers(Georgetown University), Aileen I. Fernandez(Yale University), Jennifer L. Franke(Georgetown University), Manisha Mohandoss(Georgetown University), Naiem T. Issa(University of Miami)
Cited by 10
Related Papers
Examination of Low ERBB2 Protein Expression in Breast Cancer Tissue
|JAMA Oncology|2022|347
Deep learning trained on hematoxylin and eosin tumor region of Interest predicts HER2 status and trastuzumab treatment response in HER2+ breast cancer
|Modern Pathology|2021|166
Quantitative measurement of HER2 expression to subclassify ERBB2 unamplified breast cancer
|Laboratory Investigation|2022|141
Multi-institutional Assessment of Pathologist Scoring HER2 Immunohistochemistry
|Modern Pathology|2023|98
Discovery of Biomarkers of Resistance to Immune Checkpoint Blockade in NSCLC Using High-Plex Digital Spatial Profiling
|Journal of Thoracic Oncology|2022|40